Published in Thromb Haemost on June 12, 2012
Simulated Thrombin Generation in the Presence of Surface-Bound Heparin and Circulating Tissue Factor. Ann Biomed Eng (2015) 0.77
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Thrombin functions during tissue factor-induced blood coagulation. Blood (2002) 3.42
Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation (2008) 2.64
A model for the stoichiometric regulation of blood coagulation. J Biol Chem (2002) 2.43
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol (2005) 2.10
Pros and cons of thrombophilia testing: pros. J Thromb Haemost (2003) 2.09
Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation (1999) 1.89
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol (1997) 1.77
"Normal" thrombin generation. Blood (1999) 1.74
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 1.67
Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol (1994) 1.66
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. J Am Coll Surg (2010) 1.47
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood (1991) 1.37
The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost (2005) 1.35
Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost (1993) 1.29
Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost (1991) 1.13
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood (2006) 1.10
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol (2008) 1.05
Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. Immunology (2002) 1.01
Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost (2009) 1.00
Simulated surface-induced thrombin generation in a flow field. Biophys J (2011) 0.87
Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res (2005) 0.87
Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost (1996) 0.84
Some properties of antithrombin-III and its concentration in human plasma. Thromb Res (1980) 0.84
Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost (1999) 0.82
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. Br J Haematol (2001) 0.78
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA (2007) 3.50
Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46
Risk assessment for recurrent venous thrombosis. Lancet (2010) 3.31
Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med (2006) 3.13
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet (2003) 2.98
Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85
Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med (2006) 2.75
Gene variants associated with deep vein thrombosis. JAMA (2008) 2.74
Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology (2006) 2.62
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ (2013) 2.45
Hypoglycemia is associated with intensive care unit mortality. Crit Care Med (2010) 2.41
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev (2014) 2.28
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med (2009) 2.16
Risks of oral anticoagulant therapy with increasing age. Arch Intern Med (2005) 2.06
Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med (2004) 2.00
Is an EMA review on hormonal contraception and thrombosis needed? BMJ (2013) 1.94
Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol (2008) 1.93
A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg (2012) 1.89
2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol (2009) 1.86
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost (2003) 1.80
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood (2011) 1.78
Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation (2006) 1.77
Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol (2004) 1.72
Multiple SNP testing improves risk prediction of first venous thrombosis. Blood (2012) 1.70
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA (2004) 1.70
Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol (2004) 1.69
Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg (2012) 1.65
Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg (2002) 1.64
Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry. J Vasc Surg (2012) 1.63
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol (2007) 1.61
Accuracy of administrative data versus clinical data to evaluate carotid endarterectomy and carotid stenting. J Vasc Surg (2013) 1.59
Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg (2013) 1.57
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology (2004) 1.57
Reporting standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg (2010) 1.56
Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol (2010) 1.55
Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? Blood (2013) 1.54
Carotid endarterectomy in asymptomatic patients with limited life expectancy. Stroke (2012) 1.54
Results of endovascular aortic aneurysm repair with general, regional, and local/monitored anesthesia care in the American College of Surgeons National Surgical Quality Improvement Program database. J Vasc Surg (2011) 1.53
Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood (2006) 1.52
Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture. J Vasc Surg (2012) 1.52
Carbohydrate and protein immobilization onto solid surfaces by sequential Diels-Alder and azide-alkyne cycloadditions. Bioconjug Chem (2006) 1.51
The effect of flight-related behaviour on the risk of venous thrombosis after air travel. Br J Haematol (2008) 1.50
Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol (2008) 1.49
Trends in vena caval interruption. J Vasc Surg (2010) 1.49
Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol (2006) 1.47
Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation (2007) 1.47
The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood (2013) 1.47
Surgical management of descending thoracic aortic disease: open and endovascular approaches: a scientific statement from the American Heart Association. Circulation (2010) 1.47
An activation-specific platelet inhibitor that can be turned on/off by medically used hypothermia. Arterioscler Thromb Vasc Biol (2011) 1.46
Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood (2005) 1.46
Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost (2009) 1.46
The impact of endovascular procedures on fellowship training in lower extremity revascularization. J Vasc Surg (2012) 1.44
Bleeding in carriers of hemophilia. Blood (2006) 1.41
Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol (2002) 1.41
Prothrombotic gene variation in patients with large and small vessel disease. Neuroepidemiology (2008) 1.40
Fluid loss does not explain coagulation activation during air travel. Thromb Haemost (2008) 1.38
Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol (2006) 1.34
Viscoelastic and mechanical behavior of recombinant protein elastomers. Biomaterials (2005) 1.31
Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med (2006) 1.27
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt. Biomaterials (2006) 1.24
D-periodic collagen-mimetic microfibers. J Am Chem Soc (2007) 1.24
Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev (2007) 1.24
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol (2002) 1.22
Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke (2002) 1.21
Micelle density regulated by a reversible switch of protein secondary structure. J Am Chem Soc (2006) 1.21
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med (2005) 1.20
A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation (2012) 1.19
Biomaterials for vascular tissue engineering. Regen Med (2010) 1.19
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood (2006) 1.18
Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood (2010) 1.17
Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol (2009) 1.17
A prospective evaluation of hypogastric artery embolization in endovascular aortoiliac aneurysm repair. J Vasc Surg (2002) 1.16
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 1.16
Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol (2010) 1.16
Alterations in physical cross-linking modulate mechanical properties of two-phase protein polymer networks. Biomacromolecules (2005) 1.16
Elastin-mimetic protein polymers capable of physical and chemical crosslinking. Biomaterials (2008) 1.15
Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica (2009) 1.15
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol (2003) 1.14
Layer-by-layer assembly of a conformal nanothin PEG coating for intraportal islet transplantation. Nano Lett (2008) 1.14
Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol (2005) 1.12
Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology (2012) 1.11
Covered stent exclusion of dialysis access pseudoaneurysms. J Surg Res (2002) 1.10
Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol (2011) 1.10
Novel thromboresistant materials. J Vasc Surg (2007) 1.10
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood (2004) 1.10